Serial Number:
90838107
Mark:
ZENBEXUS
Status:
Third Extension-Granted
Status Date:
04-05-2024
Filing Date:
Registration Number:
N/A
Registration Date:
N/A
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical and biological preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders, and monoclonal antibodies for medical use
Mark Description:
The mark consists of the word "ZENBEXUS" in blue stylized font except for a red stylized "X" with yellow curved lines forming an ellipse design.
Class:
Pharmaceutical and veterinary preparations
Type of Mark:
Trademark
Published for Opposition Date:
09-06-2022
Owner:
Mark Drawing Status:
Design plus Words, Letters, and/or Numbers
Abandon Date:
N/A
Business Name:
BRISTOL-MYERS SQUIBB COMPANY
Correspondent Name:
